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Introduction
Esophageal adenocarcinoma (EAC), including cancers of the 
gastro-esophageal junction, represent a substantial health concern 
in Western countries due to its increasing incidence and poor prog-
nosis. To date, there are no widely accepted animal models for 
EAC and a limited number of cell lines are all that are available 
for in vitro functional studies. Recent genome-wide sequencing 
projects have shown that EAC is one of the most highly mutated 
solid cancers with a high degree of heterogeneity (Dulak et al., 
2013; Weaver et al., 2014). In addition to point mutations there 
are also widespread copy number alterations with evidence of 
catastrophic events such as chromothripsis and bridge fusion 
breakages in about one-third of cases (Nones et al., 2014). An 
accurate annotation of the mutational landscape of available EAC 
cell lines is therefore crucial for optimal experimental design, 
interpretation of genotype-phenotype data and to analyse drug 
sensitivities. We selected eight EAC cell lines—ESO26, ESO51, 
FLO-1, JH-EsoAd1, OACM5.1 C, OACP4 C, OE33, SK-GT-4—
the identities of which have been verified by short tandem repeat 
(STR) analysis, p53 mutation and xenograft histology against the 
original tumors (Boonstra et al., 2010), and one esophageal high 
grade dysplasia (CP-D) cell line. We performed high-coverage 
paired-end whole genome sequencing and aligned the sequence 
data to the human reference genome in order to detect single 
nucleotide variants, indels and copy number alterations.
Materials and methods
Ethics
Cell lines were obtained through commercially available reposi-
tories except JH-EsoAd1, which was a kind gift from Hector 
Alvarez (Table 1).
Cell lines
All cell lines were from a certified source (Table 1) and verified in 
house for >90% match with publicly reported STR profiles. Cell 
lines were mycoplasma tested and grown in standard conditions 
reported in cell repositories indicated in Table 1. Matched germline 
DNA was not available.
Library preparation, sequencing and QC
Genomic DNA was prepared from cultured cells with AllPrep-
DNA/RNA Mini Kit (Qiagen) according to manufacturer’s 
instructions. A single library was created for each sample, and 
90-bp paired-end sequencing was performed at Beijing Genomic 
Institute (BGI, Guangdong, China) according to Illumina (Ca, 
USA) instructions to a typical depth of 30×, with 94% of the known 
genome being sequenced to at least 10× coverage and achieving 
a Phred quality of 30 for at least 80% of mapping bases. FastQC 
0.11.2 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc) 
was used to assess the quality of the sequence data. Additional 
alignment, duplication and insert size metrics quality metrics 
are reported in Supplementary material 7. Sequence reads were 
mapped to the human reference genome (Ensembl GRCh37, 
release 84) using BWA 0.5.9 (Li, 2009), sorted into genome coordi-
nate order and duplicates marked using Picard 1.105 (FixMateInfor-
mation and MarkDuplicates tools respectively, http://broadinstitute.
github.io/picard). Original BAM files are available in the European 
Bioinformatics Institute (EBI) repository (project: PRJEB14018; 
sample accessions: ERS1158075-ERS1158083).
Mutation calling
GATK v3.2.2 (Broad Institute, MA, USA) was used to call and 
filter single nucleotide and indel variants compared to the reference 
genome. In brief, the steps run were as follows: 1) local realign-
ment of reads to correct misalignments around indels using GATK 
RealignerTargetCreator and IndelRealigner tools; 2) recalibration 
of base quality scores using GATK BaseRecalibrator tool; 3) SNV 
and indel calling using GATK HaplotypeCaller which determines 
haplotype by re-assembly within regions determined to be active, 
i.e. where there is evidence for a variation, and uses a Bayesian 
approach to assign genotypes. Hard filters were applied to the 
resulting call set using recommendations available from the GATK 
documentation (https://www.broadinstitute.org/gatk) to generate a 
high-confidence set of SNV and indel calls. These were analyzed 
with Ensembl Variant Effect Predictor (release 75, http://www.
ensembl.org/info/docs/tools/vep/index.html) to annotate with 
genomic features and consequences of protein coding regions 
(Supplementary material 4). For the purposes of the analysis, all 
variants with global minor allele frequency (GMAF) >0.0014 
described in the 1000 Genomes project were separated out as likely 
germline polymorphisms (The 1000 Genomes Project Consor-
tium et al., 2012) according to the criteria adopted in the Cosmic 
Cell Lines Project (Wellcome Trust Sanger Institute, Cambridge). 
Further, we removed all SNPs that have a minor allele frequency 
in the DBSNP (Ensembl v.58) and variants with a frequency 
≥0.00025 in the ESP6500 (NHLBI GO Exome Sequencing Project, 
released June 20th 2012). A full list of the filtered variants is 
available in Supplementary material 4 and Supplementary material 6.
Copy number assessment
Copy number (CN) analysis was carried out using Control-FREEC 
(Boeva et al., 2012). Control-FREEC computes and segments CN 
profiles and is capable of characterizing over-diploid genomes, 
taking into consideration the CG-content and mapability profiles 
to normalize read count in the absence of a control sample. Ploidy 
in each cell line was assessed interactively with the Crambled 
app v.2.0 according to the methods described by Lynch (2015).
Dataset validation
Whole genome sequencing
We identified a median of 1.3×105 variants across all 9 cell lines 
(range 105,487–151,879; Figure 1a, Table 2, Supplementary 
material 3, Supplementary material 4). We found that 1,5% of the 
variants were in coding regions; additionally, 4% fell in surround-
ing gene regions (i.e. regulatory as defined in Zerbino et al. (2015), 
upstream and downstream regions), 41% in introns and 23% in inter-
genic regions. Among the variants in the coding sequence, the major-
ity, 57.4%, were in the UTR regions, followed by exonic missense 
and synonymous variants (21% and 11% respectively (Figure 1, 
Table 2, Supplementary material 3, Supplementary material 4). The 
number of variations identified in the high-grade dysplasia CP-D 
line was not significantly lower to the median of other EAC cell 
lines, consistent with the finding that such pre-malignant lesions 
have already accumulated many SNVs (Weaver et al., 2014). 
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Figure 1. Distribution of detected variants and coding sequence consequences (mean percentage value). A) Bar chart showing the 
distribution of called variants across various regions of the genome as indicated; B) Details of the coding sequence variants identified by 
the Variant Effect Predictor (Ensembl) expressed as a mean percentage value of all cell lines (values were not statistically different among 
samples).
OACP4C and ESO26 showed the smallest and largest number of 
variants, respectively. (Figure 1, Table 2).
A limitation of this study is represented by the lack of an avail-
able normal counterpart. In order to overcome this problem, in 
addition to the GATK calling pipeline we have applied a series of 
filters according to the criteria reported in methods and derived the 
1000 Genomes Project (The 1000 Genomes Project Consortium 
et al., 2012), DBSNP (Ensembl v.58) and ESP6500 (released 
June 20th 2012). This approach reduced the number of variants by 
an order of magnitude from the original GATK pipeline (from a 
median of 4.1×106 to 1.3×105). Yet, the abundance of called variants 
compared to a range of 4,8×103-6×104 reported in human EAC 
(Weaver et al., 2014), may indicate that a proportion of the variants 
called in our final annotation are of germline origin. Also, addi-
tional mutations may have accumulated in vitro. A comprehensive 
annotation of the coding sequence variants identified is reported in 
Supplementary material 3 and Supplementary material 4.
Analysis of putative EAC driver genes
In order to investigate how closely cell lines reflect the spectrum 
of mutations observed in human specimens we analysed the muta-
tional landscape of known cancer and putative EAC driver genes 
and compared to the previously reported mutation rate (Dulak 
et al., 2013; Weaver et al., 2014; Figure 2b & 2c). 69% of EACs 
have TP53 mutations (Weaver et al., 2014), while all cell lines 
carried at least one deleterious TP53 mutation. A SMAD4 muta-
tion was present in 2 of 9 cell lines, ESO26 and JH-EsoAd, 
consistent with the 13% observed in EAC (Weaver et al., 2014). 
We were not able to identify mutations in ARID1A (affected by 
UTR variants in 1 of 9 cell lines) that is reportedly mutated in about 
10% of cases of EAC specimens. Only some of the missense vari-
ants in the genes shown in Figure 2b resulted in known pathogenic 
mutations (i.e. TP53, PIK3CA, and TLR4). Other genes harboured 
benign or likely benign variants and/or variants with uncertain 
functional significance.
We expanded our analysis to other cancer genes of potential rel-
evance to OAC. We identified a pathogenic KRAS mutation 
in SKGT4, and a missense mutation of uncertain significance 
in MET (OE33), EGFR (CP-D, ESO26, IH-EsoAd1). Among 
DNA repair genes all cell lines carry benign missense variants of 
ATM and missense variants of uncertain significance in BRCA2. 
MSH2 is affected by a missense variant in SKGT4, splice site 
variants in CP-D, JH-EsoAd1, and UTR variants in ESO51 and 
OACP4 C (Supplementary material 3, Supplementary material 4, 
Supplementary material 6). Copy number analysis (Supplementary 
material 1, Supplementary material 2) identified recurrent ampli-
fications in ERBB2, MYC, MET and SEMA5A, and deletions 
in SMAD4, CDKN2A, CCDC102B and SMARCA4.
A B
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This sequencing data will enable the research commu-
nity to undertake and interpret further analyses (reviewed in 
Supplementary material 5) and to inform the use of these cell 
lines as a model of EAC. Our data highlight the need to develop 
additional in vitro models that have a germline reference genome 
to identify clearly the somatic changes (Gazdar et al., 1998). A 
larger number of cell lines might also more closely recapitulate the 
range of mutations observed in human disease.
Data availability
BAM files are available at the European Nucleotide Archive (ENA, 
EMBL-EBI, www.ebi.ac.uk/ena, Study PRJEB14018). Accession 
numbers: CP-D ERS1158083; SK-GT-4 ERS1158082; OE33 
ERS1158081; OACP4 C ERS1158080; OACM5.1 ERS1158079; 
JH-EsoAd1 ERS1158078; FLO-1 ERS1158077; ES051 
ERS1158076; ES026 ERS1158075.
Author contributions
GC collected and analysed the data, ME, AGL, MS and LB 
carried out bioinformatic analysis, RFE and JW contributed to STR 
analysis and DNA preparation, RCF, PAWE and GC conceived 
the study and wrote the manuscript. RCF and PAWE obtained 
funding for the study.
Figure 2. Analysis SNV and CNA of putative EAC genes identified in Dulak et al. (2013) and Weaver et al. (2014). A) Log ratio of 
copy number status of the selected genes computed with Control-Freec (green indicates CN gain and red CN loss). Genome wide CN for 
each line is available in Supplementary material 1 and Supplementary material 3. B) SNVs identified by our pipelines and annotated by 
Variant Effect Predictor analysis (Ensembl). When more than one variant was present in a single gene, the most deleterious was annotated 
according to the color-coded legend reported at the bottom of the figure. A complete annotation of identified SNV are available in the 
Supplementary material 2. C) Blue and red bars indicate the mutation rate of EAC genes reported in Dulak et al., 2013; and Weaver 
et al., 2014, respectively.
A B C
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Supplementary material
Supplementary material 1. A) Copy Number Alteration of EAC cell lines according to ploidy shown by FREEC plots (loss, normal, and 
gain are indicated in blue, green and red, respectively). Genes annotated in red are the genes of the Cancer Genes Cosmic Census that fall in 
the amplified regions defined as copy number ≥5 for diploid and ≥7 for triploid and tetraploid cell lines. Genes annotated in blue are genes 
of the Cancer Genes Cosmic Census that fall in deleted regions with CN ≤1. B) Tables reporting all the genes of the Cancer Genes Cosmic 
Census that falls in deleted or amplified regions according to FREEC. Cell lines are shown in the following order 1) CP-D, 2) ESO26, 
3) ESO51, 4) FLO-1, 5) JH-EsoAd1, 6) OACM5.1 C, 7) OACP4 C, 8) OE33, 9) SK-GT-4.
Supplementary material 2. FREEC output of CNV by chromosome of the analysed cell lines. CNV of each cell line is indicated by 
chromosome consistently to known ploidy and in silico verification with the Crambled App (Lynch et al., 2015).
Supplementary material 3. Effect Predictor Analysis annotated VCF files of GAKT called variants for CP-D, ESO26, ESO51, FLO-1, 
JH-EsoAd1, OACM5.1 C, OACP4 C, OE33, SK-GT-4 are available for download at the EMBL-EBI European Variation Archive (EVA, 
http://www.ebi.ac.uk/eva/) under the study PRJEB14018).
Supplementary material 4. Filtered variants: 1) CP-D, 2) ESO26, 3) ESO51, 4) FLO-1, 5) JH-EsoAd1, 6) OACM5.1 C, 7) OACP4 C, 
8) OE33, 9) SK-GT-4.
Supplementary material 5. Publicly Available datasets for analysed cell lines. For each cell line, currently available datasets from 
COSMIC, the Broad-Novartis Cancer Cell Line Encyclopaedia, and GEO (Gene Expression Omnibus) are listed.
Supplementary material 6. Gitools readable file containing mutation calls for all genes. When more than one variant was present in a 
single gene, the most deleterious was annotated according to the color-coded legend reported at the bottom of the figure. Gitools is freely 
available for download at www.gitools.org (Perez-Llamas & Lopez-Bigas, 2011).
Supplementary material 7. Alignment, duplication and insert size metrics for each cell line.
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